Rapport Therapeutics, Inc. (RAPP)

NASDAQ: RAPP · Real-Time Price · USD

27.84

-0.83 (-2.90%)

At close: Mar 13, 2026, 4:00 PM EDT

27.91

+0.07 (0.25%)

After-hours: Mar 13, 2026, 7:05 PM EDT

Rapport Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Net Income	-111.48	-78.31	-34.79
Depreciation & Amortization	1.02	0.84	0.11
Stock-Based Compensation	18.86	10.24	3.53
Other Adjustments	0.64	4.82	1.32
Changes in Accounts Payable	2.22	-0.35	0.86
Changes in Accrued Expenses	6.17	0.37	5.38
Changes in Other Operating Activities	-4.88	-2.44	-3.58
Operating Cash Flow	-87.47	-64.83	-27.18
Capital Expenditures	-0.62	-2.41	-1.64
Purchases of Investments	-354.78	-377.53	-77.22
Proceeds from Sale of Investments	167.93	209.8	-
Investing Cash Flow	-187.47	-170.14	-78.86
Issuance of Common Stock	270.79	157.71	0.05
Repurchase of Common Stock	-0	-	-0
Net Common Stock Issued (Repurchased)	270.79	157.71	0.05
Issuance of Preferred Stock	-	63.91	145.22
Net Preferred Stock Issued (Repurchased)	-	63.91	145.22
Other Financing Activities	-	-	-0.13
Financing Cash Flow	270.79	221.63	145.14
Net Cash Flow	-4.16	-13.34	39.1
Free Cash Flow	-88.09	-67.23	-28.82
Free Cash Flow Per Share	-2.26	-3.24	-19.14
Levered Free Cash Flow	-107.58	-82.29	-33.66
Unlevered Free Cash Flow	-121.2	-87.04	-35.06

Updated Mar 10, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q